Drug eluting balloon
The present invention is an inflatable balloon which is enclosed by an expandable cover which becomes increasingly porous/permeable during expansion. The balloon is coated or enclosed with a matrix which contains a pharmaceutically active agent. During expansion of the balloon, the pharmaceutically active agent is released or extruded through the expandable cover into a body cavity such as an artery or vein. The present invention also provides for a method of treating a disease or condition by delivering the inflatable balloon to a particular body cavity.
1. A medical device, comprising a balloon, a biocompatible matrix and an expandable polymer cover, wherein the biocompatible matrix is disposed between the balloon and the expandable polymer cover, wherein the expandable polymer cover encloses the balloon and the biocompatible matrix, wherein the balloon comprises a plurality of pleats when the balloon is not inflated, wherein permeability of the expandable polymer cover when the balloon is inflated is greater than the permeability of the expandable polymer cover when the balloon is not inflated, wherein the biocompatible matrix comprises a thin film having a thickness ranging from 3 μm to 250 μm, wherein the biocompatible matrix comprises:
(a) dextran, alginate, amylose, amylopectin, carrageenan, carboxymethyl cellulose, gellan, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, amylopectin, hyaluronic acid, xantan, xyloglucan, chitosan-based hydrogel, peptidoglycan, proteoglycans, glucose, polysaccharides, maltose, lactose, fructose, sucrose, galactose, glucosamine, galactosamine, muramic acid, glucuronate, gluconate, fucose, trehalose, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, propylene glycol, polyoxyethylene derivatives, elastin, polyvinyl amine or poly(L-lysine), carboxymethyl cellulose (CMC), hydroxypropylmethyl cellulose (HPMC), amylopectin, hyaluronic acid, pullulan, or combinations thereof, and
(b) a macrolide drug encapsulated in a microsphere, liposome, nanogel, nanoparticle, or mixtures thereof,
wherein the macrolide drug is released into an aqueous environment for at least 25 days after the balloon is inflated.
2. The medical device of claim 1 , wherein the biocompatible matrix comprises pullulan.
3. The medical device of claim 1 , wherein the microsphere or nanoparticle is a lipid particle or lipid vesicle.
4. The medical device of claim 1 , wherein the microsphere or nanoparticle is a PLGA (poly(lactic-co-glycolic acid)) particle.
5. The medical device of claim 1 , wherein the macrolide drug is encapsulated in a microsphere or nanoparticle, and wherein the microsphere or nanoparticle comprises a polymer.
6. The medical device of claim 5 , wherein the nanoparticle has a diameter ranging from 10 nm to 1000 nm.
7. The medical device of claim 5 , wherein the polymer is biodegradable.
8. The medical device of claim 5 , wherein the macrolide drug is encapsulated in a liposome, lipid particle or lipid vesicle.
9. The medical device of claim 8 , wherein the liposome, lipid particle or lipid vesicle comprises a phospholipid, a fatty acid, a fatty acid salt, a fatty alcohol, or combinations thereof.
10. The medical device of claim 8 , wherein the liposome, lipid particle or lipid vesicle comprises phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylinositol (PI), egg phosphatidylcholine (EPC), egg phosphatidylglycerol (EPG), egg phosphatidylethanolamine (EPE), egg phosphatidylserine (EPS), egg phosphatidic acid (EPA), egg phosphatidylinositol (EPI), soy phosphatidylcholine (SPC), soy phosphatidylglycerol (SPG), soy phosphatidylethanolamine (SPE), soy phosphatidylserine (SPS), soy phosphatidic acid (SPA), soy phosphatidylinositol (SPI), dipalmitoylphosphatidylcholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylglycerol (DPPG), diolelphosphatidylglycerol (DOPG), dimyristoylphosphatidylglycerol (DMPG), hexadecylphosphocholine (HEPC), hydrogenated soy phosphatidylcholine (HSPC), distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG), dioleylphosphatidylethanolamine (DOPE), palmitoylstearoylphosphatidylcholine (PSPC), palmitoylstearoylphosphatidylglycerol (PSPG), monooleoylphosphatidylethanolamine (MOPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC), polyethyleneglycol distearoylphosphatidylethanolamine (PEG-DSPE), dipalmitoylphosphatidylserine (DPPS), 1,2-dioleoyl-sn-glycero-3-phosphatidylserine (DOPS), dimyristoylphosphatidylserine (DMPS), distearoylphosphatidylserine (DSPS), dipalmitoylphosphatidic acid (DPPA), 1,2-dioleoyl-sn-glycero-3-phosphatidic acid (DOPA), dimyristoylphosphatidic acid (DMPA), distearoylphosphatidic acid (DSPA), dipalmitoylphosphatidylinositol (DPPI), 1,2-dioleoyl-sn-glycero-3-phosphatidylinositol (DOPI), dimyristoylphosphatidylinositol (DMPI), distearoylphosphatidylinositol (DSPI), or mixtures thereof.
11. The medical device of claim 1 , wherein the biocompatible matrix further comprises the macrolide drug in a crystalline form.
12. The medical device of claim 1 , wherein the macrolide drug comprises everolimus, tacrolimus, zotarolimus, biolimus, rapamycin, or combinations thereof.
13. The medical device of claim 1 , wherein the macrolide drug is encapsulated in a liposome, lipid particle or lipid vesicle.
14. The medical device of claim 13 , wherein the liposome, lipid particle or lipid vesicle comprises phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylinositol (PI), egg phosphatidylcholine (EPC), egg phosphatidylglycerol (EPG), egg phosphatidylethanolamine (EPE), egg phosphatidylserine (EPS), egg phosphatidic acid (EPA), egg phosphatidylinositol (EPI), soy phosphatidylcholine (SPC), soy phosphatidylglycerol (SPG), soy phosphatidylethanolamine (SPE), soy phosphatidylserine (SPS), soy phosphatidic acid (SPA), soy phosphatidylinositol (SPI), dipalmitoylphosphatidylcholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylglycerol (DPPG), diolelphosphatidylglycerol (DOPG), dimyristoylphosphatidylglycerol (DMPG), hexadecylphosphocholine (HEPC), hydrogenated soy phosphatidylcholine (HSPC), distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG), dioleylphosphatidylethanolamine (DOPE), palmitoylstearoylphosphatidylcholine (PSPC), palmitoylstearoylphosphatidylglycerol (PSPG), monooleoylphosphatidylethanolamine (MOPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC), polyethyleneglycol distearoylphosphatidylethanolamine (PEG-DSPE), dipalmitoylphosphatidylserine (DPPS), 1,2-dioleoyl-sn-glycero-3-phosphatidylserine (DOPS), dimyristoylphosphatidylserine (DMPS), distearoylphosphatidylserine (DSPS), dipalmitoylphosphatidic acid (DPPA), 1,2-dioleoyl-sn-glycero-3-phosphatidic acid (DOPA), dimyristoylphosphatidic acid (DMPA), distearoylphosphatidic acid (DSPA), dipalmitoylphosphatidylinositol (DPPI), 1,2-dioleoyl-sn-glycero-3-phosphatidylinositol (DOPI), dimyristoylphosphatidylinositol (DMPI), distearoylphosphatidylinositol (DSPI), or mixtures thereof.
15. The medical device of claim 13 , wherein the biocompatible matrix further comprises the macrolide drug in a crystalline form.
16. The medical device of claim 1 , wherein the biocompatible matrix is extruded through the expandable polymer cover after inflation of the balloon.
17. The medical device of claim 1 , wherein the balloon is compliant, semi-compliant or non-compliant.
18. The medical device of claim 1 , wherein the expandable polymer cover comprises a plurality of holes, pores, slits, or combinations thereof.
19. The medical device of claim 1 , wherein the expandable polymer cover has a thickness ranging from 0.1 μm to 300 μm.
20. The medical device of claim 1 , wherein the expandable polymer cover is formed from high density, high molecular weight polyethylene (HDHMWPE), ultra-high molecular weight polyethylene (UHDHMWPE), poly(tetrafluoroethylene), poly(tetrafluoroethylene) (PTFE), ethylene vinyl acetate, latexes, urethanes, fluoropolymer, polyvinyl alcohol (PVA)-cross linked hydrogel, polysiloxanes, styrene-ethylene/butylene-styrene block copolymers, mixtures, copolymers or combinations thereof.